D-0519-2024 Class II Ongoing

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0519-2024 was initiated by Imprimis NJOF, LLC on May 14, 2024 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 74,440 units.

Recall details

Product Type
Drugs
Report Date
Jun 5, 2024
Initiation Date
May 14, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
74,440 units

Product description

Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use vial for Intraocular Injection, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-640-01

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Nationwide within the United States

Code information

Lot #: 23JUL025, Exp. Date 7/17/2024; 23SEP012, Exp. Date 7/11/2024; 23OCT015, Exp. Date 7/20/2024; 23OCT020, Exp. Date 7/25/2024; 23OCT026, Exp. Date 8/22/2024; 23NOV030, Exp. Date 8/29/2024, 23DEC026, Exp. Date 9/29/2024; 24JAN011, Exp. Date 7/21/2024; 24FEB033, Exp. Date 8/24/2024; 24JAN050, Exp. Date 8/30/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0519-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0519-2024. Report a data issue: hello@regdatalab.com.